COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03127605
Previous Study | Return to List | Next Study

Inotuzumab Ozogamicin - PF-05208773

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03127605
Expanded Access Status : Approved for marketing
First Posted : April 25, 2017
Last Update Posted : May 18, 2020
Information provided by (Responsible Party):

Tracking Information
First Submitted Date April 20, 2017
First Posted Date April 25, 2017
Last Update Posted Date May 18, 2020
Descriptive Information
Brief Title Inotuzumab Ozogamicin - PF-05208773
Official Title Not Provided
Brief Summary Inotuzumab Ozogamicin Expanded Access Program
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Not Provided
Intervention Drug: Inotuzumab Ozogamicin
Other Name: PF-05208773
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Approved for marketing
Eligibility Criteria

Inclusion Criteria:


Exclusion Criteria:


Sex/Gender Not Provided
Ages Child, Adult, Older Adult
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03127605
Other Study ID Numbers B193
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators Not Provided
PRS Account Pfizer
Verification Date May 2020